Flexion Therapeutics announces extended FDA review of sNDA for ZILRETTA®
Flexion Therapeutics announced the FDA has informed the company it needs additional time to complete the review of the supplemental New Drug Application for ZILRETTA (triamcinolone acetonide extended-release injectable suspension). The anticipated PDUFA action date was today, Oct. 14, 2019. October 14, 2019